Impact of the New York State Prescription Drug Monitoring Program (IStop) on chronic pain management by primary care providers
DOI:
https://doi.org/10.5055/jom.2021.0612Keywords:
chronic pain management, prescription drug monitoring program, IStopAbstract
Objective: To explore the impact of the New York State Prescription Drug Monitoring Program (IStop) on the self-reported management of patients with chronic pain by primary care providers.
Design: Mixed-methods study with survey collection and semistructured interviews.
Setting: Multiple academic hospitals in New York.
Participants: One hundred and thirty-six primary care providers (residents, fellows, attendings, and nurse practitioners) for survey collection, and eight primary care clinicians (residents, attending, and pharmacist) for interviews.
Interventions: Introduction of IStop.
Main outcome measure(s): Change in usage of four risk reduction strategies (pain contracts, urine tests, monthly visits, and co-management) as reported by primary care providers for patients with chronic pain.
Results: After the introduction of IStop, 25 percent (32/128) of providers increased usage of monthly visits, 28 percent (36/128) of providers increased usage of pain management co-management with other healthcare providers, and 46 percent (60/129) of providers increased usage of at least one of four risk reduction strategies. Residents indicated much higher rates of change in risk reduction strategies due to IStop usage; increasing in the use of monthly visits (32 vs. 13 percent, p = 0.02) and co-management (36 vs. 13 percent, p = 0.01) occurred at a much higher rate in residents than attending physicians. Interview themes revealed an emphasis on finding opioid alternatives when possible, the need for frequent patient visits in effective pain management, and the importance of communication between the patient and provider to protect the relationship in chronic pain management.
Conclusions: After the introduction of IStop, primary care providers have increased usage of risk reduction strategies in the care of chronic pain patients.
References
Nahin RL: Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015; 16(8): 769-780. DOI:10.1016/j.jpain.2015.05.002.
Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645. DOI:10.1001/jama.2016.1464.
Boudreau D, Von Korff M, Rutter CM, et al.: Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009; 18(12): 1166-1175. DOI:10.1002/pds.1833.
Pergolizzi J, Boger RH, Budd K, et al.: Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008; 8(4): 287-313. DOI:10.1111/j.1533-2500.2008.00204.x.
Trescot AM, Helm S, Hansen H, et al.: Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians’ (ASIPP) guidelines. Pain Physician. 2008; 11(2 Suppl): S5-S62.
Stoicea N, Costa A, Periel L, et al.: Current perspectives on the opioid crisis in the US healthcare system: A comprehensive literature review. Medicine (Baltimore). 2019; 98(20): e15425. DOI:10.1097/md.0000000000015425.
Busse JW, Wang L, Kamaleldin M, et al.: Opioids for chronic noncancer pain: A systematic review and meta-analysis. JAMA. 2018; 320(23): 2448-2460. DOI:10.1001/jama.2018.18472.
Campbell G, Nielsen S, Larance B, et al.: Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med. 2015; 16(9): 1745-1758. DOI:10.1111/pme.12773.
Manchikanti L, Fellows B, Ailinani H, et al.: Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective. Pain Physician. 2010; 13(5): 401-435.
Daubresse M, Chang HY, Yu Y, et al.: Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care. 2013; 51(10): 870-878. DOI:10.1097/MLR.0b013e3182a95d86.
Ostling PS, Davidson KS, Anyama BO, et al.: America's opioid epidemic: A comprehensive review and look into the rising crisis. Curr Pain Headache Rep. 2018; 22(5): 32. DOI:10.1007/s11916-018-0685-5.
Hooten WM, Dvorkin J, Warner NS, et al.: Characteristics of physicians who prescribe opioids for chronic pain: A meta-narrative systematic review. J Pain Res. 2019; 12: 2261-2289. DOI:10.2147/jpr.S202376.
Chen LH, Hedegaard H, Warner M: Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief. 2014; 166: 1-8.
Hedegaard H, Warner M, Minino AM: Drug overdose deaths in the United States, 1999-2016. NCHS Data Brief. 2017; 273(294): 1-8.
Gwira Baumblatt JA, Wiedeman C, Dunn JR, et al.: Highrisk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med. 2014; 174(5): 796-801. DOI:10.1001/jamainternmed.2013.12711.
Peirce GL, Smith MJ, Abate MA, et al.: Doctor and pharmacy shopping for controlled substances. Med Care. 2012; 50(6): 494-500. DOI:10.1097/MLR.0b013e31824ebd81.
United States White House: Combatting the opioid epidemic—2019 budget fact sheet. United States White House. 2019. Available at https://www.whitehouse.gov/wp-content/uploads/2018/02/FY19-Budget-Fact-Sheet_Combatting-the-Opioid-Epidemic.pdf. Accessed January 10, 2021.
Volkow ND, McLellan TA, Cotto JH, et al.: Characteristics of opioid prescriptions in 2009. JAMA. 2011; 305(13): 1299-1301. DOI:10.1001/jama.2011.401.
Mundkur ML, Rough K, Huybrechts KF, et al.: Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiol Drug Saf. 2018; 27(5): 495-503. DOI:10.1002/pds.4322.
Garcia MC, Heilig CM, Lee SH, et al.: Opioid prescribing rates in nonmetropolitan and metropolitan counties among primary care providers using an electronic health record system—United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2019; 68(2): 25-30. DOI:10.15585/mmwr.mm6802a1.
Tong ST, Hochheimer CJ, Brooks EM, et al.: Chronic opioid prescribing in primary care: Factors and perspectives. Ann Fam Med. 2019; 17(3): 200-206. DOI:10.1370/afm.2357.
Jamison RN, Sheehan KA, Scanlan E, et al.: Beliefs and attitudes about opioid prescribing and chronic pain management: Survey of primary care providers. J Opioid Manag. 2014; 10(6): 375-382. DOI:10.5055/jom.2014.0234.
Wolfert MZ, Gilson AM, Dahl JL, et al.: Opioid analgesics for pain control: Wisconsin physicians’ knowledge, beliefs, attitudes, and prescribing practices. Pain Med. 2010; 11(3): 425-434. DOI:10.1111/j.1526-4637.2009.00761.x.
Kavukcu E, Akdeniz M, Avci HH, et al.: Chronic noncancer pain management in primary care: Family medicine physicians’ risk assessment of opioid misuse. Postgrad Med. 2015; 127(1): 22-26. DOI:10.1080/00325481.2015.993572.
Harle CA, Bauer SE, Hoang HQ, et al.: Decision support for chronic pain care: How do primary care physicians decide when to prescribe opioids? A qualitative study. BMC Fam Pract. 2015; 16: 48. DOI:10.1186/s12875-015-0264-3.
Upshur CC, Luckmann RS, Savageau JA: Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006; 21(6): 652-655. DOI:10.1111/j.1525-1497.2006.00412.x.
Hooten WM, Bruce BK: Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education. J Opioid Manag. 2011; 7(6): 417-424. DOI:10.5055/jom.2011.0082.
Pearson AC, Eldrige JS, Moeschler SM, et al.: Opioids for chronic pain: A knowledge assessment of nonpain specialty providers. J Pain Res. 2016; 9: 129-135. DOI:10.2147/jpr.S98273.
Webster F, Bremner S, Oosenbrug E, et al.: From opiophobia to overprescribing: A critical scoping review of medical education training for chronic pain. Pain Med. 2017; 18(8): 1467-1475. DOI:10.1093/pm/pnw352.
Edelman EJ, Fiellin DA: Can primary care practices help address the health crisis fueled by prescription opioids? Ann Intern Med. 2017; 166(4): 307-308. DOI:10.7326/m16-2666.
Loeser JD, Schatman ME: Chronic pain management in medical education: A disastrous omission. Postgrad Med. 2017; 129(3): 332-335. DOI:10.1080/00325481.2017.1297668.
Rice K, Ryu JE, Whitehead C, et al.: Medical trainees’ experiences of treating people with chronic pain: A lost opportunity for medical education. Acad Med. 2018; 93(5): 775-780. DOI:10.1097/acm.0000000000002053.
McCarberg BH: Pain management in primary care: Strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011; 123(2): 119-130. DOI:10.3810/pgm.2011.03.2270.
Starrels JL, Becker WC, Weiner MG, et al.: Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med. 2011; 26(9): 958-964. DOI:10.1007/s11606-011-1648-2.
Khalid L, Liebschutz JM, Xuan Z, et al.: Adherence to prescription opioid monitoring guidelines among residents and attending physicians in the primary care setting. Pain Med. 2015; 16(3): 480-487. DOI:10.1111/pme.12602.
Anderson D, Zlateva I, Khatri K, et al.: Using health information technology to improve adherence to opioid prescribing guidelines in primary care. Clin J Pain. 2015; 31(6): 573-579. DOI:10.1097/ajp.0000000000000177.
Fishman SM, Bandman TB, Edwards A, et al.: The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999; 18(1): 27-37. DOI:10.1016/s0885-3924(99)00035-4.
Wallace LS, Keenum AJ, Roskos SE, et al.: Development and validation of a low-literacy opioid contract. J Pain. 2007; 8(10): 759-766. DOI:10.1016/j.jpain.2007.05.004.
Hariharan J, Lamb GC, Neuner JM: Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007; 22(4): 485-490. DOI:10.1007/s11606-006-0084-1.
Philpot LM, Ramar P, Elrashidi MY, et al.: Controlled substance agreements for opioids in a primary care practice. J Pharm Policy Pract. 2017; 10: 29. DOI:10.1186/s40545-017-0119-5.
Deep K: Use of narcotics contracts. Virtual Mentor. 2013; 15(5): 416-420. DOI:10.1001/virtualmentor.2013.15.5.ecas3-1305.
Mahajan G: Role of urine drug testing in the current opioid epidemic. Anesth Analg. 2017; 125(6): 2094-2104. DOI:10.1213/ane.0000000000002565.
Pergolizzi J, Pappagallo M, Stauffer J, et al.: The role of urine drug testing for patients on opioid therapy. Pain Pract. 2010; 10(6): 497-507. DOI:10.1111/j.1533-2500.2010.00375.x.
Christo PJ, Manchikanti L, Ruan X, et al.: Urine drug testing in chronic pain. Pain Physician. 2011; 14(2): 123-143.
Ceasar R, Chang J, Zamora K, et al.: Primary care providers’ experiences with urine toxicology tests to manage prescription opioid misuse and substance use among chronic noncancer pain patients in safety net health care settings. Subst Abus. 2016; 37(1): 154-160. DOI:10.1080/08897077.2015.1132293.
Cone EJ, Caplan YH: Urine toxicology testing in chronic pain management. Postgrad Med. 2009; 121(4): 91-102. DOI:10.3810/pgm.2009.07.2035.
Fine PG, Portenoy RK: Establishing “best practices” for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage. 2009; 38(3): 418-425. DOI:10.1016/j.jpainsymman.2009.06.002.
Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130. DOI:10.1016/j.jpain.2008.10.008.
Chelimsky TC, Fischer RL, Levin JB, et al.: The primary practice physician program for chronic pain ((c) 4PCP): Outcomes of a primary physician-pain specialist collaboration for community-based training and support. Clin J Pain. 2013; 29(12): 1036-1043. DOI:10.1097/AJP.0b013e3182851584.
Dorflinger L, Moore B, Goulet J, et al.: A partnered approach to opioid management, guideline concordant care and the stepped care model of pain management. J Gen Intern Med. 2014; 29(Suppl. 4): 870-876. DOI:10.1007/s11606-014-3019-2.
Prescription Drug Monitoring Program Training and Technical Assistance Center: Prescription Drug Monitoring Program Information. Prescription Drug Monitoring Program Statutes and Regulations Table, 2020. Available at https://www.pdmpassist.org/pdf/PDMP_Statutes_and_Regulations_Table_20200324.pdf. Accessed August 1, 2019.
Suffoletto B, Lynch M, Pacella CB, et al.: The effect of a statewide mandatory prescription drug monitoring program on opioid prescribing by emergency medicine providers across 15 hospitals in a single health system. J Pain. 2018; 19(4): 430-438. DOI:10.1016/j.jpain.2017.11.010.
Wen H, Schackman BR, Aden B, et al.: States with prescription drug monitoring mandates saw a reduction in opioids prescribed to medicaid enrollees. Health Aff (Millwood). 2017; 36(4): 733-741. DOI:10.1377/hlthaff.2016.1141.
Moyo P, Simoni-Wastila L, Griffin BA, et al.: Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US states. Addiction. 2017; 112(10): 1784-1796. DOI:10.1111/add.13860.
Lin DH, Lucas E, Murimi IB, et al.: Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP). Addiction. 2017; 112(2): 311-319. DOI:10.1111/add.13620.
Bao Y, Pan Y, Taylor A, et al.: Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016; 35(6): 1045-1051. DOI:10.1377/hlthaff.2015.1673.
Rutkow L, Chang HY, Daubresse M, et al.: Effect of Florida's prescription drug monitoring program and pill mill laws on opioid prescribing and use. JAMA Intern Med. 2015; 175(10): 1642-1649. DOI:10.1001/jamainternmed.2015.3931.
Chang HY, Lyapustina T, Rutkow L, et al.: Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis. Drug Alcohol Depend. 2016; 165: 1-8. DOI:10.1016/j.drugalcdep.2016.04.033.
Reifler LM, Droz D, Bailey JE, et al.: Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3): 434-442. DOI:10.1111/j.1526-4637.2012.01327.x.
Patrick SW, Fry CE, Jones TF, et al.: Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016; 35(7): 1324-1332. DOI:10.1377/hlthaff.2015.1496.
Ali MM, Dowd WN, Classen T, et al.: Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health. Addict Behav. 2017; 69: 65-77. DOI:10.1016/j.addbeh.2017.01.011.
Brown R, Riley MR, Ulrich L, et al.: Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity. Drug Alcohol Depend. 2017; 178: 348-354. DOI:10.1016/j.drugalcdep.2017.05.023.
Leichtling GJ, Irvine JM, Hildebran C, et al.: Clinicians’ use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 2017; 18(6): 1063-1069. DOI:10.1093/pm/pnw251.
Carnes NA, Wright ER, Norwood CW: A qualitative analysis of prescribers’ and dispensers’ views on improving prescription drug monitoring programs. Res Social Adm Pharm. 2017; 13(6): 1167-1174. DOI:10.1016/j.sapharm.2016.12.002.
Blum CJ, Nelson LS, Hoffman RS: A survey of physicians' perspectives on the New York State mandatory prescription monitoring program (ISTOP). J Subst Abuse Treat. 2016; 70: 35-43. DOI:10.1016/j.jsat.2016.07.013.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
